Tobin Schilke - 15 Mar 2023 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Mar 2023
Net transactions value
-$114,600
Form type
4
Filing time
17 Mar 2023, 15:21:53 UTC
Previous filing
02 Mar 2023
Next filing
04 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Tax liability $114,600 -3,739 -5.1% $30.65 69,483 15 Mar 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the"RSA") for 7,540 shares. The RSA vests in three equal annual installments from March 15, 2021.